Merck and Moderna reported positive Phase III INTerpath-001 results for intismeran (mRNA-4157/V940) combined with pembrolizumab in stage IIB–IV cutaneous melanoma, according to reporting tied to the trial update. The bespoke mRNA-LNP program uses an AI platform to generate individualized tumor-targeting payloads, aiming to improve outcomes beyond pembrolizumab alone. The trial, which enrolled more than 1,100 participants, compared pembrolizumab monotherapy against pembrolizumab plus intismeran, with dosing continuing under “unacceptable toxicity” stopping rules. The results described in the update point to improved recurrence/metastasis and survival signals versus the control arm. If confirmed in full regulatory-grade disclosures, the program would represent the first bespoke mRNA immunotherapy to complete Phase 3—an inflection point for patient-specific oncology formats that blend immuno-oncology and machine-designed product development.